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Photodegraded nifedipine has been shown to
increase uptake of nontransferrin bound iron into
erythroid cells. If iron could be loaded into keratino-
cytes, it might be possible to exploit epidermal des-
quamation for the purpose of eliminating potentially
toxic amounts of iron from the body. We investi-
gated the ability of photodegraded nifedipine to
stimulate iron transport and accumulation in human
epidermal keratinocytes. Nifedipine was degraded to
its nitroso derivative by exposure to sunlight. 59Fe
uptake was measured in keratinocyte monolayers,
and total iron content was measured in strati®ed epi-
dermal cultures. Photodegraded nifedipine increased
iron uptake into keratinocytes 80-fold compared to
controls. The effect of photodegraded nifedipine on
iron uptake was rapid, was concentration dependent
and occurred at physiologically relevant concentra-
tions of nonprotein-bound iron. Stimulation of iron
uptake by photodegraded nifedipine was independent
of transferrin and worked equally well in the
presence or absence of serum proteins. Iron content
in keratinocytes was increased 3-fold by four daily
treatments with photodegraded nifedipine. The
increased iron content resulting from photodegraded
nifedipine treatment was retained during a 4 d
washout period. Photodegraded nifedipine may be a
way delivering clinically signi®cant amounts of iron
to the epidermis. Key words: desquamation/hemochroma-
tosis/skin/treatment J Invest Dermatol 116:774±777, 2001
A
signi®cant proportion of the iron absorbed from the
diet is eliminated through the skin. Mitchell and
Hamilton were the ®rst to recognize that iron loss
through the skin made an important contribution to
overall iron homeostasis (Mitchell and Hamilton,
1949). Approximately 1 mg of iron is absorbed from the diet per
day, and this is matched by loss through stool, urine, and skin.
Following parenteral injection of radioactive iron, Green et al
(1968) calculated that 0.2±0.3 mg iron per d was delivered to the
epidermis. In patients with erythrodermic psoriasis, desquamated
skin cells accounted for up to 38% of total body iron loss
(Reizenstein et al, 1968). Daily loss of iron through cell-free sweat
is now thought to be minimal (Brune et al, 1986).
Previous thinking about iron loss through epidermal desquama-
tion has focused on its potential role in contributing to iron
de®ciency states (Apte and Venkatachalam, 1962; Molin and
Wester, 1976). But the issue can be viewed differently. Can iron
loss through desquamation be augmented to the extent that
desquamation could be harnessed to remediate conditions of iron
overload? Such dermatoremediation of iron overload would
require a method to enhance both iron uptake and storage in
keratinocytes.
Iron transport into erythrocytes (Savigni and Morgan, 1996) and
gallium transport into CHO cells (Luttropp et al, 1999) are greatly
enhanced by photodegraded nifedipine (PDN). Nifedipine, itself,
has no effect on iron transport, but exposure to ¯uorescent light for
4 h completely converts solutions of nifedipine to a nitroso
derivative, which is the biologically active chemical in PDN
(Savigni and Morgan, 1996; Morton KA, unpublished). The
mechanism of PDN action is unknown, but it is clearly independ-
ent of transferrin-mediated endocytosis (Luttropp et al, 1999).
At a minimum, methods to remediate iron overload through
epidermal desquamation must cause a quantitatively suf®cient
increase in iron transport into keratinocytes to have a systemic
effect and must result in iron accumulation, not simply reversible
transport. The purpose of the studies described herein was to
measure and characterize the effect of PDN on iron uptake and
retention in keratinocytes.
MATERIALS AND METHODS
Photodegradation of nifedipine A 10 mM solution of nifedipine
(Sigma, St. Louis, MO) in ethanol was exposed to direct outdoor
daylight in a 1.5 ml polypropylene microfuge tube for exactly 1 h.
Photodegradation was monitored by thin layer chromatography on silica
gel 60 F254 (EM Industries, Gibbstown, NJ) using a hexane:
chloroform:acetone (50:30:20) solvent (Savigni and Morgan, 1996). The
thin layer chromatograph was then photographed on an ultraviolet light
box.
Keratinocyte cultures Human keratinocytes were obtained from
neonatal foreskins and grown in cMCDB as previously described (Zhou
et al, 1999). For monolayer experiments we used keratinocytes from
passages 3±5 that were grown to con¯uence in six-well plates (9 cm2 per
well). For experiments using strati®ed cultures, the medium was changed
at con¯uence to Dulbecco's modi®ed Eagle's medium (DMEM)/
F12 + 10% fetal bovine serum to permit strati®cation during an
additional week of culture (Zhou et al, 1999).
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Iron solutions For all uptake experiments, incubation medium
contained 15 mM iron, unless otherwise stated. 59FeCl3 (Dupont NEN,
Fe-59 chloride sp. act. 14.5 mCi per mg) was mixed with a 20 mM
stock solution of 56FeCl3 (Fisher Scienti®c, Fair Lawn, NJ) in a 15 ml
centrifuge tube. Just prior to use, a molar equivalent of tricine ascorbate
made in Hanks' balanced salt solution (HBSS) was added to the iron
solution. Tricine effectively solubilizes both ferrous and ferric iron
(Brissot et al, 1985), and ascorbate is a physiologically relevant
coordinator of ferrous iron in plasma (Grootveld et al, 1989). The HBSS,
pH 7.2±7.4, contained 1 mM CaCl2, 1 mM MgCl2, and 3.7 g per liter
NaHCO3 (Luttropp et al, 1999). The iron/tricine ascorbate solution was
allowed to equilibrate uncapped at 37°C in a 4% CO2 incubator for
30 min prior to use.
Measurement of iron uptake The following was adapted from
Luttropp et al (1999). Keratinocyte monolayers were washed with
phosphate-buffered saline (PBS) and then preincubated for 2 h at 37°C
in 2 ml serum-free DMEM (Gibco Laboratories, Grand Island, NY) to
deplete cells of transferrin. The preincubation medium was removed and
replaced with 1 ml of iron uptake medium containing 15 mM iron
(Luttropp et al, 1999). Unless otherwise indicated, the incubation
solution for the experimental group contained PDN, 25 mM in ethanol,
and the medium for the control group received an equal amount of
solvent (ethanol). Cells were incubated in a 4% CO2 incubator at 37°C
for varying intervals of time, depending on the experiment. At the end
of the incubation period, dishes were immediately placed on ice, the
incubation medium was removed by aspiration, and the cells were
washed once with ice-cold calcium magnesium free PBS (CMF-PBS)
and then twice with CMF-PBS prewarmed to 37°C. To obtain a cell
suspension, monolayers were trypsinized with 700 ml 0.05% trypsin +
ethylenediamine tetraacetic acid at 37°C for 3±4 min. The cells and
trypsin were collected and carefully layered over a 200 ml column of
dibutylphthalate:paraf®n oil (8.5:1.5) in 1.5 ml tubes and centrifuged at
11,000 rpm for 2 min to separate the cells from residual extracellular
radioactivity. The supernatant was aspirated and the pellet was recovered
using a microfuge tube clipper to harvest the bottom of the tube into a
counting vial containing a 900 ml solution of 200 mmol per liter NaOH
and 1% sodium dodecyl sulfate. Radioactivity in the dissolved cell pellets
was determined by gamma counting (CompuGamma 1282, LKB Wallac,
Gaithersburg, MD).
Analytical methods Iron content was measured in strati®ed cultures
that had been washed extensively with CMF-PBS both before and after
scraping the epithelia from the dishes. Washed epithelia were placed in
tared tubes, dried, weighed, and analyzed for iron content by inductively
coupled plasma mass spectrometry (Mayolabs, Rochester, MN). Protein
content in aliquots of dissolved cell pellets was measured by the cuprous
bicinchoninic acid colorometric method using a commercially available
kit (Pierce Chemical, Rockford, IL), a microtiter plate reader (Bio-Tech
Instuments, Winooski, VT), and bovine serum albumin as reference.
RESULTS
Photodegradation of nifedipine Solutions of nifedipine were
exposed to daylight and analyzed by thin layer chromatography.
The starting material was converted to a single product within
30 min and showed no further degradation at 1 h (Fig 1).
Characterization of the effect of PDN on iron uptake in
keratinocytes Uptake of radioactive iron into untreated
keratinocyte monolayers was slow and linear over 3 h, under
conditions that intentionally excluded transferrin-mediated iron
uptake. Iron uptake was stimulated in the presence of PDN. PDN-
stimulated uptake was linear for the ®rst 30 min and then slowly
reached a plateau (Fig 2). In this experiment, uptake at 30 min in
the PDN-treated cultures was 87-fold greater than in the controls.
In the presence of PDN, iron uptake was equal over the range of
pH 6.5±7.5, whereas in the absence of PDN, iron uptake into
keratinocytes showed a clear optimum at pH 6.5 (Fig 3). The
PDN stimulation of iron uptake was temperature dependent, as
Figure 1. Thin layer chromatography of PDN. Samples of 10 mM
nifedipine were exposed to daylight for increasing times and analyzed by
thin layer chromatography. For nifedipine (N), Rf = 0.68, and for its
major degradation product (PDN), Rf = 0.76.
Figure 2. Time course of iron uptake in keratinocytes treated
with PDN. Keratinocyte monolayers were incubated for varying times
in 15 mM iron with 25 mM PDN (j) or with solvent (r). 59Fe uptake
into cells was measured as described in Methods and cell number was
determined in a parallel set of dishes. Each point is the mean of three
samples 6 SD for a representative experiment.
Figure 3. Effect of pH on iron uptake in keratinocytes.
Keratinocyte monolayers were incubated for 20 min in 15 mM iron with
25 mM PDN (j) or with solvent (r). Iron solutions were made in
isotonic saline buffered with 20 mM PIPES at the indicated pH. 59Fe
uptake into cells was measured by gamma counting. Each point is the
mean of three samples 6 SD.
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previously described (Savigni and Morgan, 1996); at 4°C there was
no difference between PDN-treated and control cultures (data not
shown).
Iron uptake into keratinocytes was stimulated over a broad range
of PDN concentrations (Fig 4). Threshold for stimulation was at
1±3 mM PDN, and stimulation began to plateau at about 30 mM
PDN.
PDN stimulated iron uptake into keratinocytes at physiologically
relevant concentrations of extracellular iron (Fig 5). Nonprotein-
bound iron in serum of normal individuals ranges from 0.5 to 1.0
mM; in patients with severe iron overload nonprotein-bound iron
concentrations are 5±15 mM (Batey et al, 1980). At an extracellular
iron concentration of 1 mM, PDN stimulated iron uptake 77-fold;
at 5 mM extracellular iron PDN stimulated uptake 100-fold (Fig 5).
In most in vivo situations, the majority of iron transport into cells
occurs through transferrin-mediated endocytosis. All previous
assays of PDN on iron uptake were performed in the absence of
all serum proteins, including transferrin. To test whether serum or
transferrin had any effect on PDN stimulation of iron uptake,
experiments were performed in serum-containing medium instead
of the usual medium. Stimulation of iron uptake by PDN was at
least as great in cells that had been grown and assayed in the
presence of serum as in those grown and assayed in the absence of
serum (data not shown).
Effect of PDN on iron accumulation and retention in
keratinocytes Total iron content was measured in
keratinocytes to determine whether the stimulation of iron
uptake by PDN resulted in a signi®cant net increase in cellular
iron. For these experiments, cultures of strati®ed cells were treated
repeatedly on successive days for 1 h and then harvested for
measurement of iron content. After four treatments with PDN,
keratinocytes in the PDN-treated cultures had three times the iron
content of cultures that had not been treated with PDN (Fig 6, day
4). In a parallel set of cultures treated for 4 d with PDN and then
maintained an additional 4 d in fresh medium without PDN, the
iron content of PDN-treated cells remained 3-fold higher than the
iron content of cells that had never been exposed to PDN (Fig 6,
day 8). Long-term exposure to PDN had no obvious effects on
growth or morphology.
DISCUSSION
PDN stimulates iron uptake at least 70-fold in keratinocytes,
consistent with previous work showing that PDN stimulates iron
uptake 4-fold in erythrocytes (Savigni and Morgan, 1996) and
stimulates gallium uptake 1000-fold in CHO cells (Luttropp et al,
1999). The characteristics of PDN-stimulated iron uptake in
keratinocytes are all similar to PDN-stimulated iron uptake in
erythrocytes: dependence on PDN concentration; relation to iron
concentration; pH optimum; time course and temperature depend-
ence. Quantitative differences in stimulation caused by PDN could
be related to intrinsic differences in cell types or to small differences
in assay conditions. Our minimum stimulatory dose of PDN was
1±3 mM, whereas others reported stimulation with as little as 0.25
mM (Luttropp et al, 1999). Variations in conditions of photode-
gradation may account for such discrepancies. Use of the puri®ed,
active product in the future should help resolve the reason for these
quantitative differences. The active component in PDN responsible
for stimulating iron and gallium uptake is now known to be the
fully aromatic nitroso derivative of nifedipine (Morton KA,
unpublished).
The mechanism by which PDN has its effect on cation transport
has not been elucidated (reviewed in Luttropp et al, 1999).
Available data indicate that PDN has a much more pronounced
effect on ferrous than ferric ion transport, that it fails to stimulate
Figure 4. Effect of PDN concentration of iron uptake in
keratinocytes. Keratinocyte monolayers were incubated for 20 min in
15 mM iron with varying amounts of PDN (j). 59Fe uptake into cells
was measured by gamma counting. Each point is the mean of three
samples 6 SD.
Figure 5. Effect of iron concentration on PDN-stimulated iron
uptake in keratinocytes. Keratinocyte monolayers were incubated for
20 min in varying concentrations of iron with 25 mM PDN (j) or with
solvent (r). Each sample had an equal amount of 59Fe adjusted with
cold 56Fe to give the desired iron concentration. Cell number was
determined in a parallel set of dishes. Each point is the mean of three
samples 6 SD.
Figure 6. Effect of PDN on iron content of keratinocytes.
Strati®ed cultures of keratinocytes were exposed for 1 h, daily for 4 d, to
20 mM iron with 25 mM PDN (j) or with solvent (o), washed, and
then returned to standard culture medium. Some cultures were
maintained for an additional 4 d (day 8) without further exposure to
PDN or supplemental iron. Iron content in washed epithelia was
measured by mass spectrometry. Each bar is the mean of three cultures
6 SD.
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Mn2+ transport or transferrin-mediated iron uptake, and that its
action is not inhibited by NaCl, valinomycin, or amiloride (Savigni
and Morgan, 1996). Whether PDN acts on the divalent metal
cation transporter DMT1 (Gunshin et al, 1997) or some other iron
transporter or channel remains an open question.
Enhanced uptake of a potential systemic toxin into keratinocytes
will only be an effective remedy if the toxin is retained in the
keratinocyte until that cell is desquamated. Previous studies of PDN
focused on transport of iron, not on its retention or storage. The
studies in erythrocytes had demonstrated that PDN could stimulate
iron ef¯ux as well as uptake, but that the effect on ef¯ux was
detected only in the presence of PDN and an iron chelator (Savigni
et al, 1996). The previous studies, as well as ours, show that PDN-
enhanced transport is complete within 2 h. The question, then, was
what effect this enhanced transport would have on net iron
content. We found that PDN not only enhanced iron transport but
also led to a large increase in iron content in keratinocytes. The
®nding that the additional iron was retained in those cells for at least
4 d after exposure to PDN, without obvious effect on growth or
morphology, has particular signi®cance.
The amount of iron lost through skin, but not the amount lost in
urine, correlates with body stores (Green et al, 1968). In conditions
of systemic iron overload, considerably more iron is delivered to
the skin (Green et al, 1968) and stored in epidermis (Friedlaender et
al, 1988) than in normal conditions. This means that epidermis has
the capacity to accumulate and store additional iron in vivo, just as
our cultured keratinocytes did in vitro.
Patients with hereditary hemochromatosis absorb two to ®ve
times the normal 1±1.5 mg of dietary iron per d. Increasing the
iron content in epidermis by a daily treatment with PDN could go
a long way toward reducing the lifetime burden of total body iron
accumulation. Our initial in vitro data justify further studies of the
mechanism of action of PDN, its toxicity pro®le, and its action in
epidermis in vivo.
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